Pfizer partners Biocon of India for biosimilar insulin products
This article was originally published in Scrip
Executive Summary
Pfizer continues to build on its Indian links in the area of generics, this time for follow-on biologics. It has struck a deal with Biocon, India's largest biotechnology company by revenue, to commercialise Biocon's biosimilar versions of insulin and insulin analogue products – recombinant human insulin, glargine, aspart and lispro - for upfront payments of $200 million and certain additional development, milestone and sales-linked payments.